Category
    Regions
    Category
    Regions
    Reset Showing 1 – 10 of 1555
    Zynex Inc. SWOT, Financial and Strategic Analysis Report 2025

    Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zynex Inc.. Zynex Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zynex Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zynex Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zynex Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zynex Inc. and all latest updates of the company are provided. The 2025 version of Zynex Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Zynerba Pharmaceuticals Inc. SWOT, Financial and Strategic Analysis Report 2025

    Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zynerba Pharmaceuticals Inc.. Zynerba Pharmaceuticals Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zynerba Pharmaceuticals Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zynerba Pharmaceuticals Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zynerba Pharmaceuticals Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zynerba Pharmaceuticals Inc. and all latest updates of the company are provided. The 2025 version of Zynerba Pharmaceuticals Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Zur Rose Group AG SWOT, Financial and Strategic Analysis Report 2025

    Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. It offers consumer health, beauty, and personal care products. The company also provides medicines management services. It operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. Zur Rose Group AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zur Rose Group AG. Zur Rose Group AG business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zur Rose Group AG are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zur Rose Group AG , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zur Rose Group AG including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zur Rose Group AG and all latest updates of the company are provided. The 2025 version of Zur Rose Group AG report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Zivo Bioscience Inc. SWOT, Financial and Strategic Analysis Report 2025

    ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Bloomfield Hills, Michigan. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zivo Bioscience Inc.. Zivo Bioscience Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zivo Bioscience Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zivo Bioscience Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zivo Bioscience Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zivo Bioscience Inc. and all latest updates of the company are provided. The 2025 version of Zivo Bioscience Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Zentalis Pharmaceuticals Inc. SWOT, Financial and Strategic Analysis Report 2025

    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zentalis Pharmaceuticals Inc.. Zentalis Pharmaceuticals Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zentalis Pharmaceuticals Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zentalis Pharmaceuticals Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zentalis Pharmaceuticals Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zentalis Pharmaceuticals Inc. and all latest updates of the company are provided. The 2025 version of Zentalis Pharmaceuticals Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Zealand Pharma SWOT, Financial and Strategic Analysis Report 2025

    Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Zealand Pharma. Zealand Pharma business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Zealand Pharma are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Zealand Pharma , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Zealand Pharma including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Zealand Pharma and all latest updates of the company are provided. The 2025 version of Zealand Pharma report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Yulong Eco-Materials Limited SWOT, Financial and Strategic Analysis Report 2025

    EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Yulong Eco-Materials Limited. Yulong Eco-Materials Limited business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Yulong Eco-Materials Limited are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Yulong Eco-Materials Limited , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Yulong Eco-Materials Limited including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Yulong Eco-Materials Limited and all latest updates of the company are provided. The 2025 version of Yulong Eco-Materials Limited report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Ypsomed Holding AG SWOT, Financial and Strategic Analysis Report 2025

    Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Ypsomed Holding AG. Ypsomed Holding AG business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Ypsomed Holding AG are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Ypsomed Holding AG , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Ypsomed Holding AG including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Ypsomed Holding AG and all latest updates of the company are provided. The 2025 version of Ypsomed Holding AG report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Y-mAbs Therapeutics Inc. SWOT, Financial and Strategic Analysis Report 2025

    Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Y-mAbs Therapeutics Inc.. Y-mAbs Therapeutics Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Y-mAbs Therapeutics Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Y-mAbs Therapeutics Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Y-mAbs Therapeutics Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Y-mAbs Therapeutics Inc. and all latest updates of the company are provided. The 2025 version of Y-mAbs Therapeutics Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Xtant Medical Holdings Inc. SWOT, Financial and Strategic Analysis Report 2025

    Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Xtant Medical Holdings Inc.. Xtant Medical Holdings Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Xtant Medical Holdings Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Xtant Medical Holdings Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Xtant Medical Holdings Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Xtant Medical Holdings Inc. and all latest updates of the company are provided. The 2025 version of Xtant Medical Holdings Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Oct-2025

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF